Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Long-Term Deferred Tax (2016 - 2025)

Sanofi's Long-Term Deferred Tax history spans 7 years, with the latest figure at $6.9 billion for Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax rose 25.96% year-over-year to $6.9 billion; the TTM value through Dec 2023 reached $6.9 billion, up 25.96%, while the annual FY2023 figure was $7.0 billion, 22.58% up from the prior year.
  • Long-Term Deferred Tax for Q4 2023 was $6.9 billion at Sanofi, up from $5.5 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $6.9 billion in Q4 2023 and bottomed at $5.0 billion in Q4 2020.
  • The 4-year median for Long-Term Deferred Tax is $5.4 billion (2021), against an average of $5.7 billion.
  • The largest annual shift saw Long-Term Deferred Tax rose 4.37% in 2022 before it grew 25.96% in 2023.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $5.0 billion in 2020, then grew by 5.64% to $5.3 billion in 2021, then rose by 4.37% to $5.5 billion in 2022, then rose by 25.96% to $6.9 billion in 2023.
  • Per Business Quant, the three most recent readings for SNY's Long-Term Deferred Tax are $6.9 billion (Q4 2023), $5.5 billion (Q4 2022), and $5.3 billion (Q4 2021).